^
Association details:
| Biomarker: | EGFR T790M + TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
1369P - EGFR T790M ctDNA abundance and TP53 co-mutation by next generation sequencing predicted clinical outcomes of osimertinib in non-small cell lung cancer patients from a real-world study
Published date:
09/14/2020
Excerpt:
The study compromised 23 advanced EGFR T790M-mutated NSCLC patients...TP53 was the most common co-occurring mutations and led to shorter osimertinib-related PFS (mPFS for patients with or without TP53 co-mutation were 8.00±1.02 and 15.00±4.43months, HR=4.40, 95%CI: 0.82-23.49, log-rank P=0.042).
